In CKD, empagliflozin reduced kidney disease progression at a median 2 y, regardless of primary kidney disease type
- PMID: 38560913
- DOI: 10.7326/J24-0020
In CKD, empagliflozin reduced kidney disease progression at a median 2 y, regardless of primary kidney disease type
Abstract
EMPA-KIDNEY Collaborative Group. Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial. Lancet Diabetes Endocrinol. 2024;12:51-60. 38061372.
Conflict of interest statement
Comment on
-
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.Lancet Diabetes Endocrinol. 2024 Jan;12(1):51-60. doi: 10.1016/S2213-8587(23)00322-4. Epub 2023 Dec 4. Lancet Diabetes Endocrinol. 2024. PMID: 38061372 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical